Genzyme To Sanofi: How About $89-Per-Share? Answer: "Very Unrealistic"
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme is out to convince investors that Sanofi's hostile bid significantly undervalues the biotech, laying out the reasons why at a meeting in New York Oct. 23.